UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 16 von 43
Datensatz exportieren als...
BibTeX
Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer
Journal of surgical oncology, 2002-02, Vol.79 (2), p.101-106
Ng, Calvin S.H.
Zhang, Jun
Wan, Song
Lee, Tak Wai
Arifi, Ahmed A.
Mok, Tony
Lo, Dennis Y.M.
Yim, Anthony P.C.
2002
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Ng, Calvin S.H.
Zhang, Jun
Wan, Song
Lee, Tak Wai
Arifi, Ahmed A.
Mok, Tony
Lo, Dennis Y.M.
Yim, Anthony P.C.
Titel
Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer
Ist Teil von
Journal of surgical oncology, 2002-02, Vol.79 (2), p.101-106
Ort / Verlag
New York: John Wiley & Sons, Inc
Erscheinungsjahr
2002
Quelle
MEDLINE
Beschreibungen/Notizen
Background and Objectives The inactivation of the tumor suppressor gene p16 by methylation (p16M) has been recognized recently as an important process in the oncogenesis for a variety of carcinomas. There have been few reports of its use in lung cancer. We investigate p16M in patients with non–small cell lung cancer (NSCLC). Methods p16M in tumor, plasma, and pleural lavage fluid from patients with resectable NSCLC were investigated by using methylation‐specific polymerase chain reaction. Results Of the 33 patients studied, 14 (42%) had p16M tumors. There was a significant association between p16M tumors and advanced TNM staging (stage III or IV, P = 0.047, Fisher exact test). Circulating p16M was identified in 2 of the 14 patients with p16M tumor and was also associated with advanced TNM staging (P = 0.049). The presence of plasma p16M in NSCLC patients and in p16M tumor patients was associated with poor survival and shorter disease‐free survival (P = 0.0028, P = 0.0039, Kaplan‐Meier log rank). In addition, p16M was present in three preresectional and four postresectional lavage samples. Preresectional p16M was associated with poor survival and shorter disease‐free survival (P = 0.0085). p16M tumor involving the visceral pleura was significantly associated with positive p16M postresectional lavage. Conclusions Positive tumor and plasma p16M indicate advanced staging in NSCLC. Patients with plasma and preresection pleural lavage p16M have shorter survival. Further research in this direction is warranted. J. Surg. Oncol. 2002;79:101–106. © 2002 Wiley‐Liss, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0022-4790
eISSN: 1096-9098
DOI: 10.1002/jso.10046
Titel-ID: cdi_proquest_miscellaneous_754879495
Format
–
Schlagworte
Adult
,
Aged
,
Aged, 80 and over
,
Biological and medical sciences
,
Biomarkers, Tumor - analysis
,
Bronchoalveolar Lavage Fluid - chemistry
,
Carcinoma, Non-Small-Cell Lung - pathology
,
Carcinoma, Non-Small-Cell Lung - surgery
,
Disease-Free Survival
,
DNA, Neoplasm - analysis
,
Female
,
Genes, p16
,
Humans
,
lung cancer
,
Lung Neoplasms - pathology
,
Lung Neoplasms - surgery
,
Male
,
Medical sciences
,
Methylation
,
methylation-specific polymerase chain reaction (MSPCR)
,
Middle Aged
,
Neoplasm Staging - methods
,
p16M methylation
,
pleural lavage
,
Pneumology
,
Pneumonectomy
,
Polymerase Chain Reaction
,
Prognosis
,
Prospective Studies
,
TNM stage
,
Tumors of the respiratory system and mediastinum
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX